<div id="readability-page-1"><div> <p>By Josh Beckerman</p> <pre></pre> <p>   Shares of Eton Pharmaceuticals initially rose but pared their gains after the Food and Drug Administration approved Desmoda oral solution for management of central diabetes insipidus as antidiuretic replacement therapy. </p> <p>   Prior to a trading halt before the company's announcement, shares were at $17.69. The stock peaked at $19.98 Wednesday afternoon but was recently down 1.5% for the day at $18. </p> <p>   Eton expects a March 9 commercial launch for Desmoda, an oral liquid formulation of desmopressin. The company expects product peak sales of $30 million to $50 million annually. </p> <pre></pre> <p>   Write to Josh Beckerman at josh.beckerman@wsj.com </p> <pre></pre> <p>   (END) Dow Jones Newswires</p> <p>   February 25, 2026 15:29 ET (20:29 GMT)</p><p>Copyright (c) 2026 Dow Jones &amp; Company, Inc.</p></div></div>

纳斯达克生物科技指数 ETF - iShares Nasdaq

美国制药 ETF - iShares

动态生物技术与基因组 ETF - Invesco

<p>Eton Pharmaceuticals 的股票在 FDA 批准 Desmoda 用于治疗中央性尿崩症后最初上涨，但随后下跌了 1.5%，至 18 美元。该股票在公告后最高达到 19.98 美元。Eton 计划于 3 月 9 日推出 Desmoda，预计年峰值销售额为 3000 万至 5000 万美元</p>

Eton Pharmaceuticals Rises After an FDA Approval But Pares Gains

MorningStar

医药突破 ETF - ALPS

Eton Pharmaceuticals

生物科技 ETF - VanEck Vectors

医疗业 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

Invesco Nasdaq Biotechnology ETF

标普全球医疗股指数 ETF - iShares

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

医疗业 ETF - Vanguard

2 倍做多纳斯达克生物技术 ETF - ProShares

Eton Pharmaceuticals 在获得 FDA 批准后股价上涨，但随后涨幅收窄